http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Chrishanthi Rajasooriyar,David Bernshaw,Srinivas Kondalsamy-Chennakesavan,Linda Mileshkin,Kailash Narayan 대한부인종양학회 2014 Journal of Gynecologic Oncology Vol.25 No.4
Objective: The purpose of this study was to evaluate the patterns of failure, overall survival (OS), disease-free survival (DFS) and factors influencing outcome in endometrial cancer patients who presented with metastatic lymph nodes and were treated with curative intent. Methods: One hundred and twenty-six patients treated between January 1996 to December 2008 with surgery and adjuvant radiotherapy were identified from our service’s prospective database. Radiotherapy consisted of 45 Gy in 1.8 Gy fractions to the whole pelvis. The involved nodal sites were boosted to a total dose of 50.4 to 54 Gy. Results: The 5-year OS rate was 61% and the 5-year DFS rate was 59%. Grade 3 endometrioid, serous, and clear cell histologies and involvement of upper para-aortic nodes had lower OS and DFS. The number of positive nodes did not influence survival. Among the histological groups, serous histology had the worst survival. Among the 54 patients relapsed, only three (6%) failed exclusively in the pelvis and the rest of the 94% failed in extrapelvic nodal or distant sites. Patients with grade 3 endometrioid, serous and clear cell histologies did not influence pelvic failure but had significant extrapelvic failures (p<0.001). Conclusion: Majority of node positive endometrial cancer patients fail at extrapelvic sites. The most important factors influencing survival and extrapelvic failure are grade 3 endometrioid, clear cell and serous histologies and involvement of upper para-aortic nodes.
Kailash Narayan,Sylvia van Dyk,David Bernshaw,Pearly Khaw,Linda Mileshkin,Srinivas Kondalsamy-Chennakesavan 대한부인종양학회 2014 Journal of Gynecologic Oncology Vol.25 No.3
Objective: The aim of this study was to report on the long-term results of transabdominal ultrasound guided conformal brachytherapy in patients with cervical cancer with respect to patterns of failures, treatment related toxicities and survival. Methods: Three hundred and nine patients with cervical cancer who presented to Institute between January 1999 and December 2008 were staged with magnetic resonance imaging and positron emission tomography and treated with external beam radiotherapy and high dose rate conformal image guided brachytherapy with curative intent. Follow-up data relating to sites of failure and toxicity was recorded prospectively. Results: Two hundred and ninety-two patients were available for analyses. The median (interquantile range) follow-up time was 4.1 years (range, 2.4 to 6.1 years). Five-year failure free survival and overall survival (OS) were 66% and 65%, respectively. Primary, pelvic, para-aortic, and distant failure were observed in 12.5%, 16.4%, 22%, and 23% of patients, respectively. In multivariate analysis, tumor volume and nodal disease related to survival, whereas local disease control and point A dose did not. Conclusion: Ultrasound guided conformal brachytherapy of cervix cancer has led to optimal local control and OS. The Melbourne protocol compares favorably to the more technically elaborate and expensive GEC-ESTRO recommendations. The Melbourne protocol’s technical simplicity with real-time imaging and treatment planning makes this a method of choice for treating patients with cervical cancer.
Alexander B. Olawaiye,김재원,Andrea Bagameri,Erin Bishop,Anita Chudecka-Głaz,Alix Devaux,Laurence Gladieff,Mary E. Gordinier,Jacob Korach,Michael E. McCollum,Linda Mileshkin,Bradley J. Monk,Shibani Nicum 대한부인종양학회 2024 Journal of Gynecologic Oncology Vol.35 No.4
Background: Ovarian cancer has the highest mortality among gynecologic cancers,primarily because it typically is diagnosed at a late stage and because of the developmentof chemoresistance in recurrent disease. Improving outcomes in women with platinum-resistant ovarian cancer is a substantial unmet need. Activation of the glucocorticoid receptor (GR) by cortisol has been shown to suppress the apoptotic pathways used bycytotoxic agents, limiting their efficacy. Selective GR modulation may be able to counteractcortisol’s antiapoptotic effects, enhancing chemotherapy’s efficacy. A previous phase 2study has shown that adding intermittently dosed relacorilant, a selective GR modulator,to nab-paclitaxel improved outcomes, including progression-free sur vival (PFS) and overallsur vival (OS), with minimal added toxicity, in women with recurrent platinum-resistantovarian cancer. The ROSELLA study aims to confirm and expand on these findings in a largerpopulation. Methods: ROSELLA is a phase 3, randomized, 2-arm, open-label, global multicenter studyin women with recurrent, platinum-resistant, high-grade serous epithelial ovarian, primar yperitoneal, or fallopian tube cancer. Eligible participants have received 1 to 3 lines of priorsystemic anticancer therapy, including ≥1 prior line of platinum therapy and prior treatmentwith bevacizumab, with documented progressive disease or intolerance to the most recenttherapy. There is no biomarker-based requirement for participant selection. Participantsare randomized 1:1 to receive intermittently dosed relacorilant in combination with nab-paclitaxel or nab-paclitaxel monotherapy. The study’s primar y efficacy endpoint is PFSas assessed by blinded independent central review. Secondar y efficacy endpoints includeOS, investigator-assessed PFS, objective response rate, best overall response, duration ofresponse, clinical benefit rate at 24 weeks, and cancer antigen 125 response. The study is alsoevaluating safety and patient-reported outcomes. Trial Registration: ClinicalTrials.gov Identifier: NCT05257408; European Union DrugRegulating Authorities Clinical Trials Database Identifier: 2022-000662-18